Despite facing nearly $16 billion in U.S. revenue erosion for its long-time blockbuster Humira, AbbVie reported a record-breaking $61.1 billion in total sales for 2025. This 8.6% year-over-year increase demonstrates the company’s successful transition to its next generation of immunology leaders.
The rise of the new immunology giants
The duo of Skyrizi and Rinvoq has more than compensated for the biosimilar competition affecting Humira:
-
Skyrizi: Pulled in $17.5 billion in 2025 sales, establishing itself as the company’s new primary growth engine.
-
Rinvoq: Generated $8.3 billion, steadily climbing as a preferred oral treatment option.
-
Portfolio Impact: Together with the remaining Humira sales ($4.5 billion), the trio accounted for $30.4 billion, representing a 14% growth in the immunology sector.
Dominance in the Inflammatory Bowel Disease (IBD) Arena
AbbVie is maintaining a stronghold in the competitive IBD market, which includes Crohn’s disease and ulcerative colitis, despite the entry of Johnson & Johnson’s Tremfya:
-
Frontline Leadership: Skyrizi captures 75% of new patient starts among IL-23 inhibitors in the frontline IBD setting.
-
Dual-Branding Strategy: While Skyrizi dominates early treatment, Rinvoq is positioned as a powerful second-line option for patients requiring a stronger response.
-
Head-to-Head Ambitions: AbbVie is currently conducting a head-to-head trial comparing Skyrizi with Takeda’s Entyvio to further solidify its clinical advantage.
Expanding horizons into Neuroscience and beyond
The company’s growth outlook is bolstered by a diversifying portfolio:
-
Neuroscience: Vyalev, a Parkinson’s disease therapy approved in 2024, is projected to reach blockbuster status this year following a strong initial launch.
-
New Indications: Regulatory filings for Rinvoq in non-segmental vitiligo could position it as the first systemic treatment for the autoimmune skin condition.
-
Future Guidance: AbbVie expects 2026 sales to reach $67 billion. The combined revenue for Skyrizi and Rinvoq is now on track to hit $34.5 billion in 2026, significantly exceeding previous forecasts.
While AbbVie expressed disappointment over Botox’s inclusion in the Inflation Reduction Act (IRA) price negotiations, leadership remains confident in its long-term guidance, forecasting high single-digit revenue growth through 2029.